Nanomedicine for glaucoma: Liposomes provide sustained release of latanoprost in the eye

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 123-131

  Natarajan, Jayaganesh V ^a   Ang, Marcus ^b   Darwitan, Anastasia ^a   Chattopadhyay, Sujay ^c   Wong, Tina T ^b   Venkatraman, Subbu S ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^c INDIAN INSTITUTE OF TECHNOLOGY ROORKEE   (India)

Author keywords

EGGPC; Glaucoma; Latanoprost; Nanoliposomes; Nanomedicine; Sustained ocular delivery

Indexed keywords

CHLORAMPHENICOL; LATANOPROST; LIPOSOME; PHOSPHATIDYLCHOLINE; LIPID;

ARTICLE; DRUG FORMULATION; DRUG RELEASE; GLAUCOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDRATION; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR PRESSURE; NANOMEDICINE; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PARTITION COEFFICIENT; RABBIT; SLIT LAMP; SURGICAL TECHNIQUE; SUSTAINED DRUG RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EXPERIMENTAL RABBIT; FEMALE; LIPOSOMAL DELIVERY; NANOFABRICATION; PARTICLE SIZE; STORAGE TEMPERATURE; TREATMENT DURATION;

ADMINISTRATION, OPHTHALMIC; ANALYSIS OF VARIANCE; ANIMALS; ANTIHYPERTENSIVE AGENTS; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; EYE; FEMALE; GLAUCOMA; INJECTIONS, INTRAOCULAR; INTRAOCULAR PRESSURE; LIPOSOMES; NANOMEDICINE; PARTICLE SIZE; PHOSPHATIDYLCHOLINES; PROSTAGLANDINS F, SYNTHETIC; RABBITS;

ORYCTOLAGUS CUNICULUS;

EID: 84856639532     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
2. Nordmann J P, Auzanneau N, Ricard S, Berdeaux G. Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes. 2003;1:75.
3. Kwon YH, Kim YI, Pereira ML, Montague PR, Zimmerman MB, Alward WL. Rate of optic disc cup progression in treated primary open-angle glaucoma. J Glaucoma. 2003;12:409-416.
4. Quigley HA, Tielsch JM, Katz J, Sommer A. Rate of progression in open-angle glaucoma estimated from cross-sectional prevalence of visual feld damage. Am J Ophthalmol. 1996;122:355-363.
5. Sakai Y, Yasueda S, Ohtori A. Stability of latanoprost in an ophthalmic lipid emulsion using polyvinyl alcohol. Int J Pharm. 2005;305: 176-179.
6. Linden C, Nuija E, Alm A. Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension. Br J Ophthalmol. 1997;81:370-372.
7. Mishra G P, Bagui M, Tamboli V, Mitra AK. Recent applications of lipo-somes in ophthalmic drug delivery. J Drug Deliv. 2011;2011:863734.
8. Schaeffer HE, Krohn DL. Liposomes in topical drug delivery. Invest Ophthalmol Vis Sci. 1982;22:220-227.
9. Hathout RM, Mansour S, Mortada ND, Guinedi AS. Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS Pharm Sci Tech. 2007;8:1. http://www.aapspharmscitech.org/ view.asp?art=pt0801001. Accessed August 23, 2011.
10. Lee VH, Takemoto KA, Iimoto DS. Precorneal factors infuencing the ocular distribution of topically applied liposomal inulin. Curr Eye Res. 1984;3:585-591.
11. Hirnle E, Hirnle P, Wright JK. Distribution of liposome-incorporated carboxyfuorescein in rabbit eyes. J Microencapsul. 1991;8:391-399.
12. Hironaka K, Inokuchi Y, Tozuka Y, Shimazawa M, Hara H, Takeuchi H. Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. J Control Release. 2009;136:247-253.
13. Stewart JC. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem. 104:10-14.
14. Munger RJ. Veterinary ophthalmology in laboratory animal studies. Vet Ophthalmol. 2002;5:167-175.
15. Amano S, Nakai Y, Ko A, Inoue K, Wakakura M. A case of keratoco-nus progression associated with the use of topical latanoprost. Jpn J Ophthalmol. 2008;52(4):334-336.
16. Natarajan J V, Chattopadhyay S, Ang M, et al. Sustained release of an anti-glaucoma drug: demonstration of effcacy of a liposomal formulation in the rabbit eye. PLoS ONE. 2011;6:e24513. http://www. plosone. org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0024513. Acessed September 13, 2011.
17. Kan P, Tsao C W, Wang AJ, Su WC, Liang H F. A liposomal formulation able to incorporate a high content of paclitaxel and exert promising anticancer effect. J Drug Deliv. 2011;2011:2-10.
18. Liu J, Lee H, Huesca M, Young A, Allen C. Liposome formulation of a novel hydrophobic aryl-imidazole compound for anti-cancer therapy. Cancer Chemother Pharmacol. 2006;58:306-318.
19. Pandelidou M, Dimas K, Georgopoulos A, Hatziantoniou S, Demetzos C. Preparation and characterization of lyophilised egg PC liposomes incorporating curcumin and evaluation of its activity against colorectal cancer cell lines. J Nanosci Nanotechnol. 2011;11:1259-1266.
20. Mohammed AR, Weston N, Coombes AG, Fitzgerald M, Perrie Y. Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability. Int J Pharm. 2004;285: 23-34.
21. Perez-Soler R, Khokhar AR. Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity. Cancer Res. 1992;52:6341-6347.
22. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51:691-743.
23. Sarbolouki MN, Toliat T. Storage stability of stabilized MLV and REV liposomes containing sodium methotrexate (aqueous and lyophilized). PDA J Pharm Sci Technol. 1998;52:23-27.
24. Hernandez-Caselles T, Villalain J, Gomez-Fernandez JC. Stability of liposomes on long term storage. J Pharm Pharmacol. 1990;42: 397-400.
25. Bernsdorff C, Reszka R, Winter R. Interaction of the anticancer agent Taxol (paclitaxel) with phospholipid bilayers. J Biomed Mater Res. 1999;46:141-149.
26. Khan DR, Rezler EM, Lauer-Fields J, Fields GB. Effects of drug hydrophobicity on liposomal stability. Chem Biol Drug Des. 2008;71: 3-7.
27. Zhang B, Lu Y, Chen J, Wu W. Effects of interior gelation on pharma-cokinetics and biodistribution of liposomes encapsulating an anti-cancer drug cytarabine. J Biomed Nanotechnol. 2010;6:704-709.
28. Assil KK, Frucht-Perry J, Ziegler E, Schanzlin DJ, Schneiderman T, Weinreb RN. Tobramycin liposomes. Single subconjunctival therapy of pseudomonal keratitis. Invest Ophthalmol Vis Sci. 1991;32: 3216-3220.
29. Peyman GA, Schulman JA, Khoobehi B, Alkan HM, Tawakol ME, Mani H. Toxicity and clearance of a combination of liposome-encap-sulated ganciclovir and trifuridine. Retina. 1989;9:232-236.
30. Moon JW, Song YK, Jee J P, Kim CK, Choung HK, Hwang JM. Effect of subconjunctivally injected, liposome-bound, low-molecular-weight heparin on the absorption rate of subconjunctival hemorrhage in rabbits. Invest Ophthalmol Vis Sci. 2006;47:3968-3974.
31. Baek SH, Park SJ, Jin SE, Kim JK, Kim CK, Hwang JM. Subconjunctivally injected, liposome-encapsulated streptokinase enhances the absorption rate of subconjunctival hemorrhages in rabbits. Eur J Pharm Biopharm. 2009;72:546-551.
32. Fukushima A, Ozaki A, Ishida W, van Rooijen N, Fukata K, Ueno H. Suppression of macrophage infltration into the conjunctiva by clodronate liposomes in experimental immune-mediated blepharoconjunctivitis. Cell Biol Int. 2005;29:277-286.